Clinuvel Pharmaceuticals Ltd (CUV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clinuvel Pharmaceuticals Ltd (CUV) has a cash flow conversion efficiency ratio of 0.050x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$12.52 Million ≈ $8.86 Million USD) by net assets (AU$249.02 Million ≈ $176.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Clinuvel Pharmaceuticals Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Clinuvel Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Clinuvel Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Clinuvel Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clinuvel Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Miwon Commerci
KO:002840
|
0.074x |
|
PAM Mineral Tbk PT
JK:NICL
|
0.079x |
|
Checkpoint Therapeutics Inc
NASDAQ:CKPT
|
-0.717x |
|
IGB Commercial Real Estate Investment Trust Unit
KLSE:5299
|
0.074x |
|
Spear REIT Ltd
JSE:SEA
|
0.045x |
|
MeguREIT Israel
TA:MGRT
|
0.007x |
|
Chongqing YuXin Pingrui Electronic Co. Ltd.
SHE:301107
|
0.011x |
|
Hiyes International Co Ltd
TW:2348
|
0.010x |
Annual Cash Flow Conversion Efficiency for Clinuvel Pharmaceuticals Ltd (2001–2025)
The table below shows the annual cash flow conversion efficiency of Clinuvel Pharmaceuticals Ltd from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see Clinuvel Pharmaceuticals Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$240.81 Million ≈ $170.39 Million |
AU$41.10 Million ≈ $29.08 Million |
0.171x | -6.50% |
| 2024-06-30 | AU$203.01 Million ≈ $143.64 Million |
AU$37.05 Million ≈ $26.22 Million |
0.183x | -18.59% |
| 2023-06-30 | AU$164.63 Million ≈ $116.49 Million |
AU$36.91 Million ≈ $26.12 Million |
0.224x | -29.40% |
| 2022-06-30 | AU$125.56 Million ≈ $88.84 Million |
AU$39.87 Million ≈ $28.21 Million |
0.318x | +62.78% |
| 2021-06-30 | AU$98.74 Million ≈ $69.86 Million |
AU$19.26 Million ≈ $13.63 Million |
0.195x | -0.91% |
| 2020-06-30 | AU$72.07 Million ≈ $50.99 Million |
AU$14.19 Million ≈ $10.04 Million |
0.197x | -39.00% |
| 2019-06-30 | AU$57.18 Million ≈ $40.46 Million |
AU$18.46 Million ≈ $13.06 Million |
0.323x | +8.80% |
| 2018-06-30 | AU$39.42 Million ≈ $27.89 Million |
AU$11.69 Million ≈ $8.27 Million |
0.297x | -23.88% |
| 2017-06-30 | AU$25.44 Million ≈ $18.00 Million |
AU$9.92 Million ≈ $7.02 Million |
0.390x | +238.00% |
| 2016-06-30 | AU$17.83 Million ≈ $12.62 Million |
AU$-5.04 Million ≈ $-3.56 Million |
-0.282x | +30.14% |
| 2015-06-30 | AU$11.21 Million ≈ $7.93 Million |
AU$-4.53 Million ≈ $-3.21 Million |
-0.404x | -29.70% |
| 2014-06-30 | AU$15.43 Million ≈ $10.92 Million |
AU$-4.81 Million ≈ $-3.40 Million |
-0.312x | +37.41% |
| 2013-06-30 | AU$13.84 Million ≈ $9.79 Million |
AU$-6.89 Million ≈ $-4.88 Million |
-0.498x | +32.24% |
| 2012-06-30 | AU$13.64 Million ≈ $9.65 Million |
AU$-10.02 Million ≈ $-7.09 Million |
-0.735x | -27.11% |
| 2011-06-30 | AU$16.41 Million ≈ $11.61 Million |
AU$-9.49 Million ≈ $-6.71 Million |
-0.578x | -29.67% |
| 2010-06-30 | AU$26.43 Million ≈ $18.70 Million |
AU$-11.78 Million ≈ $-8.34 Million |
-0.446x | -50.38% |
| 2009-06-30 | AU$37.05 Million ≈ $26.22 Million |
AU$-10.99 Million ≈ $-7.77 Million |
-0.296x | -113.93% |
| 2008-06-30 | AU$51.81 Million ≈ $36.66 Million |
AU$-7.18 Million ≈ $-5.08 Million |
-0.139x | -10.81% |
| 2007-06-30 | AU$65.39 Million ≈ $46.27 Million |
AU$-8.18 Million ≈ $-5.79 Million |
-0.125x | +84.66% |
| 2006-06-30 | AU$13.99 Million ≈ $9.90 Million |
AU$-11.40 Million ≈ $-8.07 Million |
-0.815x | +34.28% |
| 2005-06-30 | AU$7.45 Million ≈ $5.27 Million |
AU$-9.25 Million ≈ $-6.54 Million |
-1.240x | -82.98% |
| 2004-06-30 | AU$8.85 Million ≈ $6.27 Million |
AU$-6.00 Million ≈ $-4.25 Million |
-0.678x | -180.66% |
| 2002-06-30 | AU$10.31 Million ≈ $7.29 Million |
AU$-2.49 Million ≈ $-1.76 Million |
-0.242x | -531.42% |
| 2001-06-30 | AU$13.45 Million ≈ $9.52 Million |
AU$-514.54K ≈ $-364.07K |
-0.038x | -- |
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with e… Read more